View in EDS

The role of molecular biomarkers in recurrent glioblastoma trials: an assessment of the current trial landscape of genome-driven oncology: an assessment of the current trial landscape of genome-driven oncology

Saved in:
Bibliographic Details
Title: The role of molecular biomarkers in recurrent glioblastoma trials: an assessment of the current trial landscape of genome-driven oncology: an assessment of the current trial landscape of genome-driven oncology
Authors: Opijnen, M.P. van, Vos, F.Y.F. de, Cuppen, E., Geurts, M., Maas, S.L.N., Broekman, M.L.D.
Contributors: MS Medische Oncologie, Brain, Cancer, CMM Groep Van Mil
Source: Med Oncol
Publisher Information: Springer Science and Business Media LLC, 2024.
Publication Year: 2024
Subject Terms: Brain Neoplasms/genetics, Original Paper, Clinical Trials as Topic, Brain Neoplasms, Molecular testing, Glioblastoma/genetics, Clinical trial, SDG 3 - Good Health and Well-being, Targeted treatment, Recurrent glioblastoma, Journal Article, Biomarkers, Tumor, Humans, Molecular Targeted Therapy, Genome-driven oncology, Biomarkers, Tumor/genetics, Neoplasm Recurrence, Local/genetics, Neoplasm Recurrence, Local, Glioblastoma, Molecular Targeted Therapy/methods
Description: For glioblastoma patients, the efficacy-targeted therapy is limited to date. Most of the molecular therapies previously studied are lacking efficacy in this population. More trials are needed to study the actual actionability of biomarkers in (recurrent) glioblastoma. This study aimed to assess the current clinical trial landscape to assess the role of molecular biomarkers in trials on recurrent glioblastoma treatment. The database ClinicalTrials.gov was used to identify not yet completed clinical trials on recurrent glioblastoma in adults. Recruiting studies were assessed to investigate the role of molecular criteria, which were retrieved as detailed as possible. Primary outcome was molecular criteria used as selection criteria for study participation. Next to this, details on moment and method of testing, and targets and drugs studied, were collected. In 76% (181/237) of the included studies, molecular criteria were not included in the study design. Of the remaining 56 studies, at least one specific genomic alteration as selection criterium for study participation was required in 33 (59%) studies. Alterations in EGFR, CDKN2A/B or C, CDK4/6, and RB were most frequently investigated, as were the corresponding drugs abemaciclib and ribociclib. Of the immunotherapies, CAR-T therapies were the most frequently studied therapies. Previously, genomics studies have revealed the presence of potentially actionable alterations in glioblastoma. Our study shows that the potential efficacy of targeted treatment is currently not translated into genome-driven trials in patients with recurrent glioblastoma. An intensification of genome-driven trials might help in providing evidence for (in)efficacy of targeted treatments.
Document Type: Article
Other literature type
File Description: application/pdf
Language: English
ISSN: 1559-131X
DOI: 10.1007/s12032-024-02501-7
Access URL: https://pubmed.ncbi.nlm.nih.gov/39316248
https://pure.eur.nl/en/publications/1965e4e6-61b4-48be-97e0-4afd26953977
https://doi.org/10.1007/s12032-024-02501-7
https://dspace.library.uu.nl/handle/1874/456368
https://hdl.handle.net/1887/4214590
Rights: CC BY
Accession Number: edsair.doi.dedup.....0c333a74debd35c6aac6b6ecc4e56e92
Database: OpenAIRE
Description
Abstract:For glioblastoma patients, the efficacy-targeted therapy is limited to date. Most of the molecular therapies previously studied are lacking efficacy in this population. More trials are needed to study the actual actionability of biomarkers in (recurrent) glioblastoma. This study aimed to assess the current clinical trial landscape to assess the role of molecular biomarkers in trials on recurrent glioblastoma treatment. The database ClinicalTrials.gov was used to identify not yet completed clinical trials on recurrent glioblastoma in adults. Recruiting studies were assessed to investigate the role of molecular criteria, which were retrieved as detailed as possible. Primary outcome was molecular criteria used as selection criteria for study participation. Next to this, details on moment and method of testing, and targets and drugs studied, were collected. In 76% (181/237) of the included studies, molecular criteria were not included in the study design. Of the remaining 56 studies, at least one specific genomic alteration as selection criterium for study participation was required in 33 (59%) studies. Alterations in EGFR, CDKN2A/B or C, CDK4/6, and RB were most frequently investigated, as were the corresponding drugs abemaciclib and ribociclib. Of the immunotherapies, CAR-T therapies were the most frequently studied therapies. Previously, genomics studies have revealed the presence of potentially actionable alterations in glioblastoma. Our study shows that the potential efficacy of targeted treatment is currently not translated into genome-driven trials in patients with recurrent glioblastoma. An intensification of genome-driven trials might help in providing evidence for (in)efficacy of targeted treatments.
ISSN:1559131X
DOI:10.1007/s12032-024-02501-7